ARHGAP20

Summary

ARHGAP20 (Rho GTPase activating protein 20, HGNC:18357) is a protein-coding gene on chromosome 11q22.3-q23.1, encoding Rho GTPase-activating protein 20 (Q9P2F6). GTPase activator for the Rho-type GTPases by converting them to an inactive GDP-bound state.

The protein encoded by this gene is an activator of RHO-type GTPases, transducing a signal from RAP1 to RHO and impacting neurite outgrowth.

Source: NCBI Gene 57569 — RefSeq curated summary.

At a glance

• GWAS associations: 15
• Clinical variants (ClinVar): 152 total
• MANE Select transcript: NM_001384657

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18357
Approved symbol	ARHGAP20
Name	Rho GTPase activating protein 20
Location	11q22.3-q23.1
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1391
Ensembl gene	ENSG00000137727
Ensembl biotype	protein_coding
OMIM	609568
Entrez	57569

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 7 protein_coding

ENST00000260283, ENST00000524756, ENST00000527598, ENST00000528829, ENST00000529591, ENST00000533353, ENST00000683387

RefSeq mRNA: 6 — MANE Select: NM_001384657 NM_001258415, NM_001258416, NM_001258417, NM_001258418, NM_001384657, NM_020809

CCDS: CCDS31673, CCDS58175, CCDS58176, CCDS58177

Canonical transcript exons

ENST00000683387 — 15 exons

Exon	Start	End
ENSE00000930480	110582321	110582435
ENSE00000930481	110583548	110583737
ENSE00001613278	110630628	110630792
ENSE00001629820	110608984	110609050
ENSE00001641278	110591977	110592155
ENSE00001650065	110606561	110606749
ENSE00001660667	110590648	110590809
ENSE00001673042	110615553	110615594
ENSE00001693862	110624162	110624311
ENSE00001763561	110611309	110611386
ENSE00001782247	110614561	110614645
ENSE00003541209	110586216	110586325
ENSE00003615655	110690547	110690629
ENSE00003917432	110712127	110712437
ENSE00003921941	110577043	110581225

Expression profiles

Bgee: expression breadth ubiquitous, 215 present calls, max score 89.56.

FANTOM5 (CAGE): breadth broad, TPM avg 3.7093 / max 113.0363, expressed in 724 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
122210	3.6108	724
122209	0.0985	46

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	89.56	gold quality
Brodmann (1909) area 46	UBERON:0006483	87.61	gold quality
cauda epididymis	UBERON:0004360	86.17	gold quality
buccal mucosa cell	CL:0002336	84.95	gold quality
endothelial cell	CL:0000115	82.17	silver quality
synovial joint	UBERON:0002217	81.92	gold quality
oocyte	CL:0000023	81.61	gold quality
seminal vesicle	UBERON:0000998	81.61	gold quality
middle temporal gyrus	UBERON:0002771	81.34	gold quality
Brodmann (1909) area 23	UBERON:0013554	79.45	gold quality
adipose tissue	UBERON:0001013	79.31	gold quality
prefrontal cortex	UBERON:0000451	79.30	gold quality
subcutaneous adipose tissue	UBERON:0002190	79.27	gold quality
urethra	UBERON:0000057	79.12	gold quality
layer of synovial tissue	UBERON:0007616	78.63	gold quality
superior frontal gyrus	UBERON:0002661	78.34	gold quality
secondary oocyte	CL:0000655	78.05	gold quality
endometrium	UBERON:0001295	77.80	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	77.60	gold quality
frontal cortex	UBERON:0001870	77.07	gold quality
stromal cell of endometrium	CL:0002255	76.88	gold quality
postcentral gyrus	UBERON:0002581	76.46	gold quality
neocortex	UBERON:0001950	75.85	gold quality
primary visual cortex	UBERON:0002436	75.83	gold quality
parietal lobe	UBERON:0001872	75.81	gold quality
adrenal tissue	UBERON:0018303	75.62	gold quality
thoracic mammary gland	UBERON:0005200	75.19	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	75.11	gold quality
occipital lobe	UBERON:0002021	75.08	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	75.03	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.45

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

129 targeting ARHGAP20, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-656-3P	100.00	72.15	2788
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-3120-5P	100.00	65.56	965
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-8082	99.95	67.27	1170

Literature-anchored findings (GeneRIF, showing 3)

• human KIAA1391 gene and mouse Kiaa1391 gene encode RhoGAP proteins with RA domain and two ANXL repeats (PMID:14532992)
• RA-RhoGAP transduces a signal from Rap1 to Rho and regulates the neurite outgrowth (PMID:16014623)
• The similar expression profiles of ARHGAP20 in 13q14 and 11q22-23 deleted CLL cases suggest a molecular connection and an intriguing mechanism of regulation (PMID:21500311)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	arhgap20	ENSDARG00000089326
danio_rerio	arhgap20b	ENSDARG00000093708
mus_musculus	Arhgap20	ENSMUSG00000053199
rattus_norvegicus	Arhgap20	ENSRNOG00000025624
drosophila_melanogaster	RhoGAP71E	FBGN0036518
caenorhabditis_elegans		WBGENE00007064

Paralogs (1): TAGAP (ENSG00000164691)

Protein

Protein identifiers

Rho GTPase-activating protein 20 — Q9P2F6 (reviewed: Q9P2F6)

Alternative names: Rho-type GTPase-activating protein 20

All UniProt accessions (2): A0A0C4DGG5, Q9P2F6

UniProt curated annotations — full annotation on UniProt →

Function. GTPase activator for the Rho-type GTPases by converting them to an inactive GDP-bound state.

Tissue specificity. Expressed predominantly in the brain. Lower expression is found in lymph nodes.

Disease relevance. A chromosomal aberration involving ARHGAP20 may be a cause of B-cell chronic lymphocytic leukemia (B-CLL). Translocation t(X;11)(q21;q23) with BRWD3 does not result in fusion transcripts but disrupts both genes.

Isoforms (4)

UniProt ID	Names	Canonical?
Q9P2F6-1	1, 1ad	yes
Q9P2F6-2	2, 1be
Q9P2F6-3	3, 1c
Q9P2F6-4	4, 1e, 1d

RefSeq proteins (6): NP_001245344, NP_001245345, NP_001245346, NP_001245347, NP_001371586, NP_065860 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000159	RA_dom	Domain
IPR000198	RhoGAP_dom	Domain
IPR001849	PH_domain	Domain
IPR008936	Rho_GTPase_activation_prot	Homologous_superfamily
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR029071	Ubiquitin-like_domsf	Homologous_superfamily
IPR047886	ARHGAP20-like_RhoGAP	Domain
IPR047887	ARHGAP20_PH	Domain
IPR047888	ARHGAP20_RA	Domain

Pfam: PF00620, PF00788, PF22286

UniProt features (40 total): helix 14, compositionally biased region 5, region of interest 5, domain 3, modified residue 3, splice variant 3, sequence variant 2, turn 2, chain 1, site 1, strand 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
3MSX	X-RAY DIFFRACTION	1.65

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9P2F6-F1	55.05	0.23

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 399 (arginine finger; crucial for gtp hydrolysis by stabilizing the transition state)

Post-translational modifications (3): 46, 704, 730

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-8980692	RHOA GTPase cycle
R-HSA-9013148	CDC42 GTPase cycle
R-HSA-9013149	RAC1 GTPase cycle

MSigDB gene sets: 147 (showing top): BENPORATH_ES_WITH_H3K27ME3, MODULE_255, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, GOBP_REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, MODULE_317, USF_C, TCF4_Q5, WANG_RESPONSE_TO_BEXAROTENE_DN, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP, GOBP_REGULATION_OF_RHO_PROTEIN_SIGNAL_TRANSDUCTION, RYTTCCTG_ETS2_B, LEF1_Q6, TAATGTG_MIR323, GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION

GO Biological Process (3): signal transduction (GO:0007165), regulation of Rho protein signal transduction (GO:0035023), regulation of small GTPase mediated signal transduction (GO:0051056)

GO Molecular Function (1): GTPase activator activity (GO:0005096)

GO Cellular Component (1): cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RHO GTPase cycle	3

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
Rho protein signal transduction	1
regulation of small GTPase mediated signal transduction	1
small GTPase-mediated signal transduction	1
regulation of intracellular signal transduction	1
GTPase activity	1
enzyme activator activity	1
GTPase regulator activity	1
cytoplasm	1
cellular anatomical structure	1

Protein interactions and networks

STRING

928 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ARHGAP20	BRWD3	Q6RI45	957
ARHGAP20	POU2AF1	Q16633	501
ARHGAP20	APBB1IP	Q7Z5R6	472
ARHGAP20	NEMP1	O14524	456
ARHGAP20	RALGDS	Q12967	453
ARHGAP20	PLCE1	Q9P212	448
ARHGAP20	TMEM248	Q9NWD8	445
ARHGAP20	AKT1	P31749	444
ARHGAP20	POU2AF2	Q8IXP5	444
ARHGAP20	PLEK2	Q9NYT0	442
ARHGAP20	ARAP2	Q8WZ64	441
ARHGAP20	PLEK	P08567	437
ARHGAP20	GLT8D2	Q9H1C3	436
ARHGAP20	LCN12	Q6JVE5	435
ARHGAP20	ARAP1	Q96P48	431

IntAct

2 interactions, top by confidence:

A	B	Type	Score
GRB2	SH3PXD2B	psi-mi:“MI:0914”(association)	0.530

BioGRID (29): ARHGAP20 (Affinity Capture-MS), ARHGAP20 (Affinity Capture-MS), ARHGAP20 (Affinity Capture-MS), ARHGAP20 (Affinity Capture-RNA), ARHGAP20 (FRET), ARHGAP20 (FRET), ARHGAP20 (FRET), DEK (Affinity Capture-MS), DNAJC11 (Affinity Capture-MS), LUC7L2 (Affinity Capture-MS), MRPL11 (Affinity Capture-MS), MRPS7 (Affinity Capture-MS), MTMR14 (Affinity Capture-MS), PLG (Affinity Capture-MS), SUB1 (Affinity Capture-MS)

ESM2 similar proteins: A0A1P8AW69, A1A4L4, A2RRS8, A2RVA7, B3H5K9, B8QB46, F4HTH8, F4KB17, P62285, P62287, P62288, P62289, P62290, P62291, P62292, P62293, P62294, P62297, Q08AX9, Q08DB0, Q0P4S5, Q0VA42, Q3B7T8, Q3UQI9, Q4R7I0, Q5HZK1, Q5JTW2, Q5ZIX8, Q6DJS0, Q6IE81, Q6IFT4, Q6ING4, Q6IRU7, Q6NPP4, Q6REY9, Q6ZEZ5, Q75PQ8, Q7ZXG4, Q8AYG3, Q8CJ27

Diamond homologs: B2RWW0, D3ZFJ3, E7EZG2, E7F3F0, F1LQX4, P0CAX8, P55194, P85298, Q07960, Q10164, Q14CB8, Q17R89, Q3KRB8, Q3UIA2, Q54WY8, Q54XT6, Q54Y72, Q55GP8, Q5F3G0, Q5FWK3, Q5SSM3, Q6IFT4, Q6P4F7, Q6REY9, Q6Y5D8, Q6ZT62, Q80Y19, Q8BL80, Q8BRH3, Q8N103, Q99N37, Q9CXP4, Q9P2F6, Q9WVM1, Q9Y3L3, O74335, P17121, Q12128, Q54YV1, Q5U2Z7

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
ARHGAP20	“down-regulates activity”	RHOA	“gtpase-activating protein”
ARHGAP20	“down-regulates activity”	RAC1	“gtpase-activating protein”
ARHGAP20	“down-regulates activity”	CDC42	“gtpase-activating protein”

Disease & clinical

Clinical variants and AI predictions

ClinVar

152 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	136
Likely benign	8
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2956 predictions. Top by Δscore:

Variant	Effect	Δscore
11:110581223:TAT:T	acceptor_gain	1.0000
11:110582317:ATAC:A	donor_loss	1.0000
11:110582319:ACCT:A	donor_loss	1.0000
11:110582320:CCTG:C	donor_loss	1.0000
11:110582431:GAAAC:G	acceptor_gain	1.0000
11:110582432:AAAC:A	acceptor_gain	1.0000
11:110582433:AAC:A	acceptor_gain	1.0000
11:110582433:AACC:A	acceptor_loss	1.0000
11:110582434:AC:A	acceptor_gain	1.0000
11:110582435:CC:C	acceptor_gain	1.0000
11:110582436:C:CA	acceptor_loss	1.0000
11:110582436:C:CC	acceptor_gain	1.0000
11:110582437:T:C	acceptor_loss	1.0000
11:110586211:ATTAC:A	donor_loss	1.0000
11:110586212:TTA:T	donor_loss	1.0000
11:110586213:TAC:T	donor_loss	1.0000
11:110586215:CCTT:C	donor_loss	1.0000
11:110586335:A:C	acceptor_gain	1.0000
11:110606553:CAACT:C	donor_loss	1.0000
11:110606554:AACTC:A	donor_loss	1.0000
11:110606555:ACTCA:A	donor_loss	1.0000
11:110606556:CTCAC:C	donor_loss	1.0000
11:110606557:TCA:T	donor_loss	1.0000
11:110606558:CA:C	donor_loss	1.0000
11:110606560:CCA:C	donor_gain	1.0000
11:110606560:CCACT:C	donor_gain	1.0000
11:110609049:CCCT:C	acceptor_gain	1.0000
11:110609050:CCT:C	acceptor_gain	1.0000
11:110609052:T:C	acceptor_gain	1.0000
11:110609052:T:TC	acceptor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000037670 (11:110698995 G>A), RS1000088545 (11:110655295 A>G), RS1000104561 (11:110700407 C>G,T), RS1000114020 (11:110678055 C>A,G), RS1000144846 (11:110592041 C>T), RS1000154094 (11:110647932 G>A,T), RS1000181359 (11:110679749 A>G), RS1000186765 (11:110620629 G>C,T), RS1000187812 (11:110615123 G>A), RS1000188620 (11:110706669 A>G), RS1000219209 (11:110620797 C>T), RS1000244980 (11:110712821 G>A), RS1000246674 (11:110649859 T>C), RS1000292569 (11:110628170 G>A), RS1000298612 (11:110713306 T>C,G)

Disease associations

OMIM: gene MIM:609568 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

15 associations (top):

Study	Trait	p-value
GCST001304_7	Renal sinus fat	8.000000e-06
GCST001806_16	Corneal structure	4.000000e-09
GCST001915_27	Alzheimer’s disease (cognitive decline)	7.000000e-07
GCST005580_176	Intraocular pressure	2.000000e-08
GCST005667_46	Central corneal thickness	4.000000e-10
GCST006412_125	Intraocular pressure	4.000000e-08
GCST007147_7	Lateral ventricular volume in normal aging	3.000000e-08
GCST008153_16	Lean body mass	4.000000e-06
GCST008317_4	Central corneal thickness	2.000000e-08
GCST009391_651	Metabolite levels	9.000000e-06
GCST010302_22	Cutaneous melanoma or hair colour	4.000000e-08
GCST010480_10	Coronary artery disease	4.000000e-08
GCST012020_138	Serum metabolite levels	5.000000e-15
GCST012020_437	Serum metabolite levels	8.000000e-12
GCST012484_20	Cerebral amyloid angiopathy x APOEe4 status interaction in Alzheimer’s disease	7.000000e-06

EFO canonical traits (9, from GWAS)

EFO ID	Trait name
EFO:0004864	renal sinus adipose tissue measurement
EFO:0004345	corneal topography
EFO:0004695	intraocular pressure measurement
EFO:0005213	central corneal thickness
EFO:0008487	lateral ventricle volume measurement
EFO:0004995	lean body mass
EFO:0007745	lactate measurement
EFO:0003924	hair color
EFO:0007659	APOE carrier status

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

21 total (human), top 21 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects cotreatment, increases expression, affects methylation	2
Acetaminophen	increases expression	2
Dexamethasone	increases expression, affects cotreatment	2
sulforaphane	decreases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
CGP 52608	affects binding, increases reaction	1
Fulvestrant	increases methylation	1
Benzo(a)pyrene	affects methylation	1
Indomethacin	affects cotreatment, increases expression	1
Lead	affects expression	1
Melphalan	decreases expression	1
Silicon Dioxide	increases expression	1
Tretinoin	increases expression	1
Triclosan	increases expression	1
Vanadates	decreases expression	1
1-Methyl-3-isobutylxanthine	increases expression, affects cotreatment	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	affects expression	1
Cyclosporine	increases expression	1
Aflatoxin B1	increases methylation	1
Okadaic Acid	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer